MAPT and Alzheimer disease: In the in vivo study, chronic dietary supplementations of EGCG (50 mg/kg for six months) in AD transgenic mice enhanced the nonamyloidogenic processing of APP and decreased Aβ levels, tau and plaques by up-regulating α-secretase activity [110].